Difference between revisions of "Team:TCU Taiwan/Project/Experimental"
Line 72: | Line 72: | ||
<br><br> | <br><br> | ||
<font size="5">Fig.1 Signiferin fusion peptide design model</font> | <font size="5">Fig.1 Signiferin fusion peptide design model</font> | ||
− | <br><br> | + | <br><br><BR><BR> |
<img src="https://static.igem.org/mediawiki/2015/3/3c/TCU_Taiwan_Signal_Peptide_2.jpeg"> | <img src="https://static.igem.org/mediawiki/2015/3/3c/TCU_Taiwan_Signal_Peptide_2.jpeg"> | ||
<br><br> | <br><br> |
Revision as of 17:02, 18 September 2015
Signal Peptide |
To increase efficiency in isolating our AMPs, we introduced a signal peptide upstream of the N-terminal of antimicrobial peptides to facilitate peptide production. This signal peptide is obtained from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). After translation process, this signal peptide will lead AMPs to the secretion system of E. coli. When the fusion peptides enter the periplasmic space, peptidase will identify the cleavage site Ala-Gln-Ala and cut at the double Ala at the signal and AMPs linkage site. This separates the signal peptide from the AMPs. To verify the E. coli secretion of AMPs to the LB culture medium, we attached an Ala at the N-terminal of AMPs.[1,2]
|
Fig.1 Signiferin fusion peptide design model
Fig.2 Epinecidin-1 fusion peptide design model
Contact us tcutaiwan@gmail.com No.701, Sec. 3, Zhongyang Rd. Hualien 97004, Taiwan |